Eye­Point sells re­main­ing rights to eye im­plant, piv­ots to tack­le an­ti-VEG­Fs

Eye­Point is sell­ing off the re­main­ing glob­al rights to its in­trav­it­re­al im­plant Yu­tiq to Al­imera, an­oth­er eye-fo­cused biotech, for $82.5 mil­lion.

Eye­Point Phar­ma­ceu­ti­cals an­nounced Thurs­day that Al­imera will re­ceive glob­al rights to Yu­tiq ex­cept in Chi­na, Hong Kong, Tai­wan, Macau and South­east Asia. Eye­Point, in 2018, grant­ed an ex­clu­sive li­cense to Oc­u­men­sion Ther­a­peu­tics, a Chi­nese biotech in those mar­kets. Eye­Point con­tin­ues to re­ceive roy­al­ties from those sales — and ex­pects to keep them for at least the next decade.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER